|
|
|
Insider
Information: |
Freund John Gordon |
Relationship: |
|
City: |
Palo Alto |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
11 |
|
Direct
Shares |
2,256,169 |
|
Indirect Shares
|
9,013,510 |
|
|
Direct
Value |
$7,258,400 |
|
|
Indirect Value
|
$19,786,628 |
|
|
Total
Shares |
11,269,679 |
|
|
Total
Value |
$27,045,028 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
3
|
Stock
price went up :
|
0
|
3
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
3.0
|
Percentage
Gain/Loss : |
0.0%
|
257.3%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Xenoport Inc |
XNPT |
Director |
2016-07-05 |
0 |
2016-07-05 |
0 |
Premium* |
|
Hansen Medical Inc |
HNSN |
Director |
2006-11-21 |
0 |
2009-04-17 |
2,000,936 |
Premium* |
|
Map Pharmaceuticals Inc |
MAPP |
Director, 10% Owner |
2011-02-14 |
1,984 |
2011-05-20 |
5,152 |
Premium* |
|
Mako Surgical Corp. |
MAKO |
Director |
|
0 |
2013-12-17 |
0 |
Premium* |
|
Acelrx Pharmaceuticals Inc |
ACRX |
10% Owner |
2011-02-16 |
0 |
2012-05-29 |
4,161,933 |
Premium* |
|
Tetraphase Pharmaceuticals Inc |
TTPH |
Director |
2019-12-10 |
0 |
2019-12-10 |
0 |
Premium* |
|
Concert Pharmaceuticals, Inc. |
CNCE |
Director, 10% Owner |
|
0 |
2014-02-20 |
1,208,920 |
Premium* |
|
Protara Therapeutics, Inc |
TARA |
Director |
2019-11-08 |
2,175,882 |
2014-10-27 |
1,432,930 |
Premium* |
|
Collegium Pharmaceutical, Inc |
COLL |
Director |
2024-05-16 |
52,468 |
2024-05-16 |
43,413 |
Premium* |
|
Sutro Biopharma Inc |
STRO |
Director |
2018-10-01 |
0 |
2020-12-10 |
56,327 |
Premium* |
|
Si-Bone, Inc. |
SIBN |
|
2023-08-09 |
25,835 |
2023-08-09 |
103,899 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
141 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
COLL |
Collegium Pharmaceutical,... |
Director |
|
2019-11-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(575,000) |
574,916 |
0 |
- |
|
COLL |
Collegium Pharmaceutical,... |
Director |
|
2019-12-02 |
4 |
D |
$0.00 |
$0 |
I/I |
(574,916) |
0 |
0 |
- |
|
COLL |
Collegium Pharmaceutical,... |
Director |
|
2019-12-02 |
4 |
A |
$0.00 |
$0 |
I/I |
8,625 |
8,625 |
0 |
- |
|
COLL |
Collegium Pharmaceutical,... |
Director |
|
2020-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
4,047 |
11,007 |
0 |
- |
|
SIBN |
Si-Bone, Inc. |
|
|
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,797 |
8,797 |
0 |
- |
|
STRO |
Sutro Biopharma Inc |
Director |
|
2020-11-09 |
4 |
A |
$0.00 |
$0 |
I/I |
118,735 |
118,735 |
0 |
- |
|
STRO |
Sutro Biopharma Inc |
Director |
|
2020-11-09 |
4 |
D |
$0.00 |
$0 |
I/I |
(560,053) |
0 |
0 |
- |
|
STRO |
Sutro Biopharma Inc |
Director |
|
2020-12-10 |
4 |
D |
$0.00 |
$0 |
I/I |
(118,735) |
0 |
0 |
- |
|
STRO |
Sutro Biopharma Inc |
Director |
|
2020-12-10 |
4 |
A |
$0.00 |
$0 |
I/I |
56,327 |
56,327 |
0 |
- |
|
COLL |
Collegium Pharmaceutical,... |
Director |
|
2021-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
9,941 |
20,948 |
0 |
- |
|
SIBN |
Si-Bone, Inc. |
|
|
2021-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
3,848 |
12,645 |
0 |
- |
|
COLL |
Collegium Pharmaceutical,... |
Director |
|
2022-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
14,035 |
34,983 |
0 |
- |
|
SIBN |
Si-Bone, Inc. |
|
|
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,324 |
20,969 |
0 |
- |
|
COLL |
Collegium Pharmaceutical,... |
Director |
|
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,792 |
44,775 |
0 |
- |
|
SIBN |
Si-Bone, Inc. |
|
|
2023-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
4,866 |
25,835 |
0 |
- |
|
COLL |
Collegium Pharmaceutical,... |
Director |
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,693 |
52,468 |
0 |
- |
|
TARA |
Protara Therapeutics, Inc |
Director |
|
2019-11-08 |
4 |
OE |
$0.99 |
$700,000 |
D/D |
703,588 |
2,175,882 |
0 |
- |
|
TTPH |
Tetraphase Pharmaceutical... |
Director |
|
2019-12-10 |
4 |
S |
$2.19 |
$31,770 |
I/I |
(14,507) |
0 |
0 |
- |
|
TTPH |
Tetraphase Pharmaceutical... |
Director |
|
2019-12-10 |
4 |
S |
$2.19 |
$1,148 |
D/D |
(524) |
0 |
0 |
- |
|
HNSN |
Hansen Medical Inc |
Director |
|
2009-04-17 |
4 |
B |
$3.25 |
$1,250,002 |
I/I |
384,616 |
2,000,936 |
2.1 |
- |
|
ACRX |
Acelrx Pharmaceuticals In... |
10% Owner |
|
2012-05-29 |
4 |
B |
$3.40 |
$967,973 |
I/I |
284,698 |
4,161,933 |
1.5 |
- |
|
XNPT |
Xenoport Inc |
Director |
|
2014-05-23 |
4 |
B |
$3.72 |
$35,354 |
I/I |
9,500 |
21,200 |
2.1 |
- |
|
XNPT |
Xenoport Inc |
Director |
|
2014-05-22 |
4 |
B |
$3.75 |
$20,623 |
I/I |
5,500 |
11,700 |
2.1 |
- |
|
XNPT |
Xenoport Inc |
Director |
|
2014-06-03 |
4 |
B |
$3.93 |
$49,164 |
I/I |
12,500 |
22,633 |
2.1 |
- |
|
TARA |
Protara Therapeutics, Inc |
Director |
|
2014-10-27 |
4 |
OE |
$4.60 |
$560,376 |
I/I |
121,760 |
1,488,968 |
0 |
- |
|
141 Records found
|
|
Page 3 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|